Nivolumab-Induced Autoimmune Haemolytic Anaemia and Safety of Subsequent Use of Ipilimumab: A Case Report

Autoimmune haemolytic anaemia (AIHA) is a rare immune-related adverse event and appears to be more common with anti-PD1/PDL1 than anti-CTLA4. Little is known about the safety of re-treating with anti-PD1/PDL1 or changing to anti-CTLA4. We present a case of grade 4 AIHA due to nivolumab (PD1-inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales: Carbó-Bagué, Anna, Fort-Culillas, Roser, Pla-Juher, Helena, Rubió-Casadevall, Jordi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460943/
https://www.ncbi.nlm.nih.gov/pubmed/34720930
http://dx.doi.org/10.1159/000518530

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460943/
https://www.ncbi.nlm.nih.gov/pubmed/34720930
http://dx.doi.org/10.1159/000518530

Ejemplares similares